TRPV1 expression regulation… A further step in defining its biology: commentary for K. Zavala et al. "The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion ...

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

Cladribine can help people with the active relapsing-remitting version of the disease, as well as more severe, highly active MS, for which it is already used, says drug advisory body NICE.

Across all comparisons (fingolimod, DMF, and teriflunomide), cladribine was associated with significantly lower relapse rates and higher treatment persistence. Compared with fingolimod ...